MEDNAX (NYSE:MD) Downgraded to Neutral at Citigroup – Riverton Roll

MEDNAX (NYSE:MD) was downgraded by analysts at Citigroup from a buy rating to a neutral rating in a research report issued to clients and investors on Friday, January 3rd, MarketBeat reports. They presently have a $29.00 target price on the stock. Citigroups price target suggests a potential upside of 7.89% from the companys previous close.

Several other research analysts have also recently weighed in on the stock. Stifel Nicolaus upgraded shares of MEDNAX from a hold rating to a buy rating and upped their price objective for the stock from $25.00 to $33.00 in a research report on Thursday, December 12th. ValuEngine upgraded shares of MEDNAX from a sell rating to a hold rating in a research report on Friday, January 3rd. Mizuho set a $25.00 target price on MEDNAX and gave the stock a hold rating in a research note on Friday, November 1st. JPMorgan Chase & Co. upped their target price on MEDNAX from $26.00 to $33.00 and gave the stock a neutral rating in a research note on Friday, December 20th. Finally, Bank of America lowered MEDNAX from a neutral rating to an underperform rating and set a $19.00 target price for the company. in a research note on Friday, September 6th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company. MEDNAX currently has a consensus rating of Hold and an average price target of $27.33.

Shares of MD opened at $26.88 on Friday. The businesss 50-day moving average price is $26.91 and its 200-day moving average price is $24.14. MEDNAX has a twelve month low of $19.93 and a twelve month high of $38.88. The stock has a market cap of $2.31 billion, a PE ratio of 7.66, a P/E/G ratio of 1.02 and a beta of 0.78. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 1.35.

MEDNAX (NYSE:MD) last announced its quarterly earnings results on Friday, November 1st. The company reported $0.91 earnings per share for the quarter, beating the Thomson Reuters consensus estimate of $0.83 by $0.08. MEDNAX had a positive return on equity of 10.38% and a negative net margin of 40.86%. The firm had revenue of $888.70 million for the quarter, compared to analysts expectations of $876.20 million. During the same period in the prior year, the business posted $0.94 earnings per share. The companys revenue was down .9% on a year-over-year basis. Analysts expect that MEDNAX will post 3.03 earnings per share for the current fiscal year.

In related news, Director Md Pascal J. Goldschmidt sold 5,000 shares of the firms stock in a transaction on Friday, November 1st. The stock was sold at an average price of $22.88, for a total value of $114,400.00. Following the completion of the sale, the director now owns 10,821 shares of the companys stock, valued at $247,584.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.40% of the companys stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Altfest L J & Co. Inc. raised its holdings in MEDNAX by 5.6% in the fourth quarter. Altfest L J & Co. Inc. now owns 9,581 shares of the companys stock worth $266,000 after purchasing an additional 510 shares in the last quarter. Millennium Management LLC increased its holdings in shares of MEDNAX by 381.5% during the third quarter. Millennium Management LLC now owns 340,081 shares of the companys stock valued at $7,692,000 after acquiring an additional 269,457 shares in the last quarter. Man Group plc increased its holdings in shares of MEDNAX by 97.9% during the third quarter. Man Group plc now owns 431,790 shares of the companys stock valued at $9,767,000 after acquiring an additional 213,629 shares in the last quarter. Voloridge Investment Management LLC purchased a new stake in shares of MEDNAX during the third quarter valued at $1,252,000. Finally, Parametric Portfolio Associates LLC boosted its position in shares of MEDNAX by 65.2% during the third quarter. Parametric Portfolio Associates LLC now owns 475,690 shares of the companys stock valued at $10,760,000 after buying an additional 187,750 shares during the last quarter. Institutional investors and hedge funds own 92.30% of the companys stock.

MEDNAX Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

MEDNAX (NYSE:MD) Downgraded to Neutral at Citigroup – Riverton Roll

Categories

Archives